FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain

FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
Drug shortages pose a significant public health threat as they can delay, and in some cases, even deny critically needed care for patients. Over the past decade, the FDA’s efforts have contributed to fewer new drug shortages and reduced the time to resolve existing drug shortages. This is due, in part, to authorities the agency now has, including those added by the Food and Drug Administration Safety and Innovation Act.